RaNA Therapeutics CEO reflects: There’s no sugarcoating the process of raising biotech venture capital. It’s hard.
There are plus and minus points when you compare public and private life sciences companies. Raising biotech venture capital is a constant grind. "I joined RaNA in November and learned very quickly that as a private company CEO, I was always going to be in capital-raising mode," RaNA Therapeutics CEO Ron Renaud says.